Related references
Note: Only part of the references are listed.Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM).
Richard D. Carvajal et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
The Molecular Pathology of Melanoma: An Integrated Taxonomy of Melanocytic Neoplasia
Boris C. Bastian
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 9 (2014)
Hippo-Independent Activation of YAP by the GNAQ Uveal Melanoma Oncogene through a Trio-Regulated Rho GTPase Signaling Circuitry
Xiaodong Feng et al.
CANCER CELL (2014)
The Phosphoinositide 3-Kinase α Selective Inhibitor BYL719 Enhances the Effect of the Protein Kinase C Inhibitor AEB071 in GNAQ/GNA11-Mutant Uveal Melanoma Cells
Elgilda Musi et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials
Keith T. Flaherty et al.
LANCET ONCOLOGY (2014)
Circulating immune cell and microRNA in patients with uveal melanoma developing metastatic disease
Susan Achberger et al.
MOLECULAR IMMUNOLOGY (2014)
Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O)
Sander Kelderman et al.
ACTA ONCOLOGICA (2013)
Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma
M. Maio et al.
ANNALS OF ONCOLOGY (2013)
BAP1 deficiency causes loss of melanocytic cell identity in uveal melanoma
Katie A. Matatall et al.
BMC CANCER (2013)
Clinical Activity of Ipilimumab for Metastatic Uveal Melanoma
Jason J. Luke et al.
CANCER (2013)
Low-Dose Irradiation Programs Macrophage Differentiation to an iNOS+/M1 Phenotype that Orchestrates Effective T Cell Immunotherapy
Felix Klug et al.
CANCER CELL (2013)
Inhibition of both BRAF and MEK in BRAFV600E mutant melanoma restores compromised dendritic cell (DC) function while having differential direct effects on DC properties
Patrick A. Ott et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advanced cancer: synergistic or antagonistic?
Jason John Luke et al.
EXPERT OPINION ON PHARMACOTHERAPY (2013)
Hypoxia inducible factor pathway inhibitors as anticancer therapeutics
Sarah K. Burroughs et al.
FUTURE MEDICINAL CHEMISTRY (2013)
Inhibition of Mutant GNAQ Signaling in Uveal Melanoma Induces AMPK-Dependent Autophagic Cell Death
Grazia Ambrosini et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a Metastatic Uveal Melanoma Model
Oliver Surriga et al.
MOLECULAR CANCER THERAPEUTICS (2013)
A Genome-wide RNAi Screen Reveals a Trio-Regulated Rho GTPase Circuitry Transducing Mitogenic Signals Initiated by G Protein-Coupled Receptors
Jose P. Vaque et al.
MOLECULAR CELL (2013)
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study
Caroline Robert et al.
LANCET ONCOLOGY (2013)
Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3
Marcel Martin et al.
NATURE GENETICS (2013)
Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma
J. William Harbour et al.
NATURE GENETICS (2013)
Ipilimumab activity in advanced uveal melanoma
Muhammad Adnan Khattak et al.
MELANOMA RESEARCH (2013)
Nivolumab plus Ipilimumab in Advanced Melanoma
Jedd D. Wolchok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
SF3B1 Mutations Are Associated with Alternative Splicing in Uveal Melanoma
Simon J. Furney et al.
CANCER DISCOVERY (2013)
The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer
Morgan O'Hayre et al.
NATURE REVIEWS CANCER (2013)
Structure-activity relationship of 2,2-dimethyl-2H-chromene based arylsulfonamide analogs of 3,4-dimethoxy-N-[(2,2-dimethyl-2H-chromen-6-yl)methyl]-N-phenylbenzenesulfonamide, a novel small molecule hypoxia inducible factor-1 (HIF-1) pathway inhibitor and anti-cancer agent
Jiyoung Mun et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
The MEK1/2 inhibitor, selumetinib (AZD6244; ARRY-142886), enhances anti-tumour efficacy when combined with conventional chemotherapeutic agents in human tumour xenograft models
S. V. Holt et al.
BRITISH JOURNAL OF CANCER (2012)
Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma
Solange Landreville et al.
CLINICAL CANCER RESEARCH (2012)
Arylsulfonamide KCN1 Inhibits In Vivo Glioma Growth and Interferes with HIF Signaling by Disrupting HIF-1α Interaction with Cofactors p300/CBP
Shaoman Yin et al.
CLINICAL CANCER RESEARCH (2012)
Combination Small Molecule MEK and PI3K Inhibition Enhances Uveal Melanoma Cell Death in a Mutant GNAQ- and GNA11-Dependent Manner
Jahan S. Khalili et al.
CLINICAL CANCER RESEARCH (2012)
Identification of Unique MEK-Dependent Genes in GNAQ Mutant Uveal Melanoma Involved in Cell Growth, Tumor Cell Invasion, and MEK Resistance
Grazia Ambrosini et al.
CLINICAL CANCER RESEARCH (2012)
New Strategies in Pleural Mesothelioma: BAP1 and NF2 as Novel Targets for Therapeutic Development and Risk Assessment
Marc Ladanyi et al.
CLINICAL CANCER RESEARCH (2012)
Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP
Yi Liu-Chittenden et al.
GENES & DEVELOPMENT (2012)
Design and in Vitro Activities of N-Alkyl-N-[(8-R-2,2-dimethyl-2H-chromen-6-yl)methyl]heteroarylsulfonamides, Novel, Small-Molecule Hypoxia Inducible Factor-1 Pathway Inhibitors and Anticancer Agents
Jiyoung Mun et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
Protein Kinase C Inhibitor AEB071 Targets Ocular Melanoma Harboring GNAQ Mutations via Effects on the PKC/Erk1/2 and PKC/NF-κB Pathways
Xinqi Wu et al.
MOLECULAR CANCER THERAPEUTICS (2012)
c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential
Xinqi Wu et al.
MELANOMA RESEARCH (2012)
A pilot study of sunitinib malate in patients with metastatic uveal melanoma
Amit Mahipal et al.
MELANOMA RESEARCH (2012)
The Protein Kinase C Inhibitor Enzastaurin Exhibits Antitumor Activity against Uveal Melanoma
Xinqi Wu et al.
PLOS ONE (2012)
KCN1, a Novel Synthetic Sulfonamide Anticancer Agent: In Vitro and In Vivo Anti-Pancreatic Cancer Activities and Preclinical Pharmacology
Wei Wang et al.
PLOS ONE (2012)
Phase II Trial of Sorafenib in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma: SWOG S0512
Shailender Bhatia et al.
PLOS ONE (2012)
Loss of the Tumor Suppressor BAP1 Causes Myeloid Transformation
Anwesha Dey et al.
SCIENCE (2012)
Binding Model for the Interaction of Anticancer Arylsulfonamides with the p300 Transcription Cofactor
Qi Shi et al.
ACS MEDICINAL CHEMISTRY LETTERS (2012)
Influence of CD8+T regulatory cells on intraocular tumor development
Kyle C. McKenna et al.
FRONTIERS IN IMMUNOLOGY (2012)
Good news-bad news: the Yin and Yang of immune privilege in the eye
John V. Forrester et al.
FRONTIERS IN IMMUNOLOGY (2012)
Ocular immune privilege and ocular melanoma: parallel universes or immunological plagiarism?
Jerry Y. Niederkorn
FRONTIERS IN IMMUNOLOGY (2012)
Sulfonamides as a new scaffold for hypoxia inducible factor pathway inhibitors
Chalet Tan et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2011)
Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin
Ahmad A. Tarhini et al.
CLINICAL CANCER RESEARCH (2011)
A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma
F. S. Hodi et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Activity of cabozantinib (XL184) in soft tissue and bone: Results of a phase II randomized discontinuation trial (RDT) in patients (pts) with advanced solid tumors.
M. S. Gordon et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers
Mohamed H. Abdel-Rahman et al.
JOURNAL OF MEDICAL GENETICS (2011)
Design and Synthesis of Novel Small-Molecule Inhibitors of the Hypoxia Inducible Factor Pathway
Suazette Reid Mooring et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Germline mutations in BAP1 predispose to melanocytic tumors
Thomas Wiesner et al.
NATURE GENETICS (2011)
Germline BAP1 mutations predispose to malignant mesothelioma
Joseph R. Testa et al.
NATURE GENETICS (2011)
NKT Cell Exacerbation of Liver Metastases Arising from Melanomas Transplanted into Either the Eyes or Spleens of Mice
Wanhua Yang et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2011)
Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma
Jo Eyles et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
In Aged Mice, Outgrowth of Intraocular Melanoma Depends on Proangiogenic M2-Type Macrophages
Long V. Ly et al.
JOURNAL OF IMMUNOLOGY (2010)
Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma
Jade Homsi et al.
MELANOMA RESEARCH (2010)
Mutations in GNA11 in Uveal Melanoma.
Catherine D. Van Raamsdonk et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Influence of Immune Privilege on Ocular Tumor Development
Kyle C. McKenna et al.
OCULAR IMMUNOLOGY AND INFLAMMATION (2010)
Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
J. William Harbour et al.
SCIENCE (2010)
Regulation of VEGF-A in Uveal Melanoma
Mariam el Filali et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2010)
Defining the Human Deubiquitinating Enzyme Interaction Landscape
Mathew E. Sowa et al.
CELL (2009)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
Catherine D. Van Raamsdonk et al.
NATURE (2009)
Activated CD11b+ CD15+ Granulocytes Increase in the Blood of Patients with Uveal Melanoma
Kyle C. McKenna et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2009)
Evidence for Natural Killer Cell-Mediated Protection from Metastasis Formation in Uveal Melanoma Patients
Willem Maat et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2009)
Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications
Mario A. Economou et al.
ACTA OPHTHALMOLOGICA (2008)
O-Mel-Inib: A Cancero-pole Nord-Ouest multicenter phase II trial of high-dose imatinib mesylate in metastatic uveal melanoma
Nicolas Penel et al.
INVESTIGATIONAL NEW DRUGS (2008)
Modulation of the tumor cell phenotype by IFN-γ results in resistance of uveal melanoma cells to granule-mediated lysis by cytotoxic lymphocytes
Kristian Hallermalm et al.
JOURNAL OF IMMUNOLOGY (2008)
Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis
Shu-Hong Chang et al.
MELANOMA RESEARCH (2008)
Monosomy of chromosome 3 and an inflammatory phenotype occur together in uveal melanoma
Willem Maat et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2008)
Oncogenic Mutations in GNAQ Occur Early in Uveal Melanoma
Michael D. Onken et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2008)
PD-L1: PD-1 interaction contributes to the functional suppression of T-cell responses to human uveal melanoma cells in vitro
Wanhua Yang et al.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (2008)
Uveal melanoma expression of indoleamine 2,3-deoxygenase: Establishment of an immune privileged environment by tryptophan depletion
Peter W. Chen et al.
EXPERIMENTAL EYE RESEARCH (2007)
Loss of heterozygosity of chromosome 3 detected with single nucleotide polymorphisms is superior to monosomy 3 for predicting metastasis in uveal melanoma
Michael D. Onken et al.
CLINICAL CANCER RESEARCH (2007)
Expression of epidermal growth factor receptor, ezrin, hepatocyte growth factor, and c-Met in uveal melanoma: An immunohistochemical study
Kandalam Mallikarjuna et al.
CURRENT EYE RESEARCH (2007)
Protein kinase C and other diacylglycerol effectors in cancer
Erin M. Griner et al.
NATURE REVIEWS CANCER (2007)
A randomized phase II trial of gemcitabine plus treosulfan versus treosulfan alone in patients with metastatic uveal melanoma
A. Schmittel et al.
ANNALS OF ONCOLOGY (2006)
Accumulation of immunosuppressive CD11b+ myeloid cells correlates with the failure to prevent tumor growth in the anterior chamber of the eye
Kyle C. McKenna et al.
JOURNAL OF IMMUNOLOGY (2006)
A prospective single arm phase II study of dacarbazine and treosulfan as first-line therapy in metastatic uveal melanoma
Penny A. O'Neill et al.
MELANOMA RESEARCH (2006)
Involvement of HIF-1 in invasion of Mum2B uveal melanoma cells
Nicole Victor et al.
CLINICAL & EXPERIMENTAL METASTASIS (2006)
Cell signalling diversity of the Gqα family of heterotrimeric G proteins
KB Hubbard et al.
CELLULAR SIGNALLING (2006)
Variates of survival in metastatic uveal melanoma
P Rietschel et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II trial of cisplatin, gemcitabine and treosulfan in patients with metastatic uveal melanoma
A Schmittel et al.
MELANOMA RESEARCH (2005)
Autocrine secretion of fas ligand shields tumor cells from fas-mediated killing by cytotoxic lymphocytes
K Hallermalm et al.
CANCER RESEARCH (2004)
The developmentally regulated neural crest-associated glycotope HNK-1 predicts metastasis in cutaneous malignant melanoma
A Thies et al.
JOURNAL OF PATHOLOGY (2004)
A phase II study of bendamustine chemotherapy as second-line treatment in metastatic uveal melanoma
M Schmidt-Hieber et al.
MELANOMA RESEARCH (2004)
Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death
MD Onken et al.
CANCER RESEARCH (2004)
Phase II evaluation of temozolomide in metastatic choroidal melanoma
AY Bedikian et al.
MELANOMA RESEARCH (2003)
Incidence of uveal melanoma in the United States: 1973-1997
AD Singh et al.
OPHTHALMOLOGY (2003)
Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma
T Kivelä et al.
EUROPEAN JOURNAL OF CANCER (2003)
Gαq Gα11 proteins mediate endothelin-1 signaling in neural crest-derived pharyngeal arch mesenchyme
K Ivey et al.
DEVELOPMENTAL BIOLOGY (2003)
Mutations of the BRAF gene in human cancer
H Davies et al.
NATURE (2002)
Expression and characterization of hypoxia-inducible factor (HIF)-3α in human kidney:: Suppression of HIF-mediated gene expression by HIF-3α
S Hara et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2001)
Neoadjuvant interferon alfa-2b treatment in a murine model for metastatic ocular melanoma - A preliminary study
S Dithmar et al.
ARCHIVES OF OPHTHALMOLOGY (2000)
Human uveal melanoma cells produce macrophage migration-inhibitory factor to prevent lysis by NK cells
AC Repp et al.
JOURNAL OF IMMUNOLOGY (2000)
Share Paper
